RANINasdaqPharmaceutical PreparationsFiscal year ends December 31

Rani Therapeutics Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.65+0.01 (+1.51%)

Close on Oct 19, 2026

Market cap: $121.72M
P/E (TTM): –
Dividend yield: –

Rani Therapeutics Holdings, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	1.63	1.03	0	0	2.72	0.46
Research & Development	20	27	40	37	26	12
General & Administrative	20	24	26	27	28	4.96
Operating Expenses	40	54	66	63	54	-17
Operating Income	-38	-53	-66	-63	-52	-17
Interest Expense	2.89	5.03	5.09	1.07	0.47	0.12
Interest & Investment Income	–	–	–	–	0.09	0.06
Asset Impairment Charges	0	3.71	0	–	–	–
Gain (Loss) on Sale of Assets	0	-0.07	0	–	–	–
Pretax Income	–	–	-68	-63	-53	-17
Income Tax Expense	0	0	0	0.07	0.04	0.04
Net Income incl. Noncontrolling Interests	-41	-57	-68	-63	-53	-17
Minority Interest in Earnings	-11	-27	-34	-33	-45	-17
Net Income	-30	-30	-34	-31	-8.33	–
EPS (Basic)(per share)	-0.45	-1.05	-1.33	-1.28	-0.43	–
EPS (Diluted)(per share)	-0.45	-1.05	-1.33	-1.28	-0.43	–
Shares Outstanding (Basic, Weighted)(shares)	0.07	0.03	0.03	0.02	0.02	–
Shares Outstanding (Diluted, Weighted)(shares)	0.07	0.03	0.03	0.02	0.02	–
EBITDA	-37	-52	-65	-63	-51	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -675.8%
Net margin: -618.0%
Return on equity, FY2025: -169.6%

Financial strength

Current ratio: 5.31
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 45.8%

Valuation

P/E ratio: –
Price to sales: 24.96
Price to book: 3.10
Dividend yield: –